بدائل البحث:
026 decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث)
μ decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), _ decreased (توسيع البحث)
we decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
50 μ » 10 μ (توسيع البحث), 5 μ (توسيع البحث)
026 decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث)
μ decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), _ decreased (توسيع البحث)
we decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
50 μ » 10 μ (توسيع البحث), 5 μ (توسيع البحث)
-
161
Antimicrobial activity of RP-1 peptide conjugate with ferrocene group
منشور في 2020"…The Fc-RP1 presented anti-amastigote activity against <i>Leishmania amazonensis</i> (IC<sub>50</sub> = 0.25 μmol L<sup>–1</sup>). In comparison with amphotericin B, a second-line drug approved for leishmaniasis treatment, (IC<sub>50</sub> = 0.63 μmol L<sup>-1</sup>), Fc-RP1 was more active and showed a 2.5-fold higher selectivity index. …"
-
162
Synthesis and Biological Evaluation of New Chalcogen Semicarbazone (<i>S</i>, <i>Se</i>) and Their Azole Derivatives against Chagas Disease
منشور في 2024"…Three compounds were selected, based on their activity against the intracellular amastigotes (EC<sub>50</sub> < 1 μM, SI > 10) and cruzain (IC<sub>50</sub> < 100 nM, SI > 5.55) which compared favorably with the approved drug, Benznidazole, and the well-established cruzain inhibitor K777. …"
-
163
Synthesis and Biological Evaluation of New Chalcogen Semicarbazone (<i>S</i>, <i>Se</i>) and Their Azole Derivatives against Chagas Disease
منشور في 2024"…Three compounds were selected, based on their activity against the intracellular amastigotes (EC<sub>50</sub> < 1 μM, SI > 10) and cruzain (IC<sub>50</sub> < 100 nM, SI > 5.55) which compared favorably with the approved drug, Benznidazole, and the well-established cruzain inhibitor K777. …"
-
164
Potent 5‑Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1–UBE2M Interaction
منشور في 2019"…After finding a novel inhibitor <b>DC-1</b> with IC<sub>50</sub> = 1.2 μM, we performed a series of chemical optimizations, which finally led to the discovery of a potent thiazole containing 5-cyano-6-phenylpyrimidin-based inhibitor <b>DC-2</b> (IC<sub>50</sub> = 15 nM). …"
-
165
-
166
Identification of druggable small molecule antagonists of the <i>Plasmodium falciparum</i> hexose transporter PfHT and assessment of ligand access to the glucose permeation pathway...
منشور في 2019"…WU-1 showed comparable potency in blocking 2-DG uptake in freed parasites and inhibiting parasite growth, with an IC<sub>50</sub> of 6.1 ± 0.8 μM and EC<sub>50</sub> of 5.5 ± 0.6 μM, respectively. …"
-
167
-
168
-
169
-
170
-
171
-
172
-
173
Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA<sub>2</sub>), UCM-14216, Ameliorates Spinal Cord Injury in Mice
منشور في 2022"…Inhibition of the type 2 lysophosphatidic acid receptor (LPA<sub>2</sub>) has recently emerged as a new potential pharmacological approach to decrease SCI-associated damage. Toward validating this receptor as a target in SCI, we have developed a new series of LPA<sub>2</sub> antagonists, among which compound <b>54</b> (UCM-14216) stands out as a potent and selective LPA<sub>2</sub> receptor antagonist (<i>E</i><sub>max</sub> = 90%, IC<sub>50</sub> = 1.9 μM, <i>K</i><sub>D</sub> = 1.3 nM; inactive at LPA<sub>1,3–6</sub> receptors). …"
-
174
Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA<sub>2</sub>), UCM-14216, Ameliorates Spinal Cord Injury in Mice
منشور في 2022"…Inhibition of the type 2 lysophosphatidic acid receptor (LPA<sub>2</sub>) has recently emerged as a new potential pharmacological approach to decrease SCI-associated damage. Toward validating this receptor as a target in SCI, we have developed a new series of LPA<sub>2</sub> antagonists, among which compound <b>54</b> (UCM-14216) stands out as a potent and selective LPA<sub>2</sub> receptor antagonist (<i>E</i><sub>max</sub> = 90%, IC<sub>50</sub> = 1.9 μM, <i>K</i><sub>D</sub> = 1.3 nM; inactive at LPA<sub>1,3–6</sub> receptors). …"
-
175
-
176
-
177
-
178
-
179
-
180
Identification of Potent DNA Gyrase Inhibitors Active against Mycobacterium tuberculosis
منشور في 2022الموضوعات: